Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 40, Issue -, Pages 125-132Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2016.02.029
Keywords
-
Funding
- NSF [CBET-1450987, DGE-1419118, DMR-1206219]
- NIH [AR064200]
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [1450987] Funding Source: National Science Foundation
Ask authors/readers for more resources
While experimental bone regeneration approaches commonly employ cells, technological hurdles prevent translation of these therapies. Alternatively, emulating the spatiotemporal cascade of endogenous factors through controlled drug delivery may provide superior bone regenerative approaches. Surgically placed drug depots have clinical indications. Additionally, noninvasive systemic delivery can be used as needed for poorly healing bone injuries. However, a major hurdle for systemic delivery is poor bone biodistribution of drugs. Thus, peptides, aptamers, and phosphate-rich compounds with specificity toward proteins, cells, and molecules within the regenerative bone microenvironment may enable the design of targeted carriers with bone biodistribution greater than that achieved by drug alone. These carriers, combined with osteoregenerative drugs and/or stimuli-sensitive linkers, may enhance bone regeneration while minimizing off-target tissue effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available